HealthQuill Regor Pharmaceuticals
Genentech, a member of the Roche Group, will acquire a portfolio of CDK inhibitors to treat breast cancer from Regor Pharmaceuticals for an upfront payment of $850 million.
Drugs Health Pharma

Roche arm to buy breast cancer portfolio from Regor for $850 million

Genentech, a member of the Roche Group, will acquire a portfolio of CDK inhibitors to treat breast cancer from Regor Pharmaceuticals for an.

Read More
X